BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

877 related articles for article (PubMed ID: 25981193)

  • 1. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
    Ebner T; Ishiguro N; Taub ME
    J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin.
    Stopfer P; Giessmann T; Hohl K; Sharma A; Ishiguro N; Taub ME; Zimdahl-Gelling H; Gansser D; Wein M; Ebner T; Müller F
    Clin Pharmacol Ther; 2016 Sep; 100(3):259-67. PubMed ID: 27256812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
    Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
    J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
    Elsby R; Martin P; Surry D; Sharma P; Fenner K
    Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.
    Ogasawara K; Wood-Horrall RN; Thomas M; Thomas M; Liu L; Liu M; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2021 Dec; 88(6):941-952. PubMed ID: 34477937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein.
    Knop J; Misaka S; Singer K; Hoier E; Müller F; Glaeser H; König J; Fromm MF
    PLoS One; 2015; 10(10):e0139370. PubMed ID: 26426900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide.
    Jeong HU; Kwon M; Lee Y; Yoo JS; Shin DH; Song IS; Lee HS
    Drug Des Devel Ther; 2015; 9():643-53. PubMed ID: 25653502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
    Rizk ML; Houle R; Chan GH; Hafey M; Rhee EG; Chu X
    Antimicrob Agents Chemother; 2014; 58(3):1294-301. PubMed ID: 24295974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interactions of lenalidomide with human uptake and efflux transporters and UDP-glucuronosyltransferase 1A1: lack of potential for drug-drug interactions.
    Tong Z; Yerramilli U; Surapaneni S; Kumar G
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):869-74. PubMed ID: 24627218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions.
    Stopfer P; Giessmann T; Hohl K; Hutzel S; Schmidt S; Gansser D; Ishiguro N; Taub ME; Sharma A; Ebner T; Müller F
    Br J Clin Pharmacol; 2018 Sep; 84(9):1941-1949. PubMed ID: 29665130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.
    Misaka S; Knop J; Singer K; Hoier E; Keiser M; Müller F; Glaeser H; König J; Fromm MF
    Mol Pharm; 2016 Feb; 13(2):512-9. PubMed ID: 26702643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
    Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
    Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous Assessment of Transporter-Mediated Drug-Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey.
    Kosa RE; Lazzaro S; Bi YA; Tierney B; Gates D; Modi S; Costales C; Rodrigues AD; Tremaine LM; Varma MV
    Drug Metab Dispos; 2018 Aug; 46(8):1179-1189. PubMed ID: 29880631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma t Antagonist, Bevurogant) on the Pharmacokinetics of a Transporter Probe Cocktail, Including Digoxin, Furosemide, Metformin, and Rosuvastatin: An Open-Label, Non-randomized, 2-Period Fixed-Sequence Trial in Healthy Subjects.
    Choi H; Huang F; Flack M
    Clin Pharmacol Drug Dev; 2024 Feb; 13(2):197-207. PubMed ID: 37960990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of Interactions Between an Antisense Oligonucleotide with 2'-O-(2-Methoxyethyl) Modifications and Major Drug Transporters.
    Yu RZ; Warren MS; Watanabe T; Nichols B; Jahic M; Huang J; Burkey J; Geary RS; Henry SP; Wang Y
    Nucleic Acid Ther; 2016 Apr; 26(2):111-7. PubMed ID: 26959999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
    Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
    Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical assessment of drug-drug interaction of fb-PMT, a novel anti-cancer thyrointegrin αvβ3 antagonist.
    Fujioka K; Fekry MI; Rumsey JM; Steiner T; Thompson D; Mousa SA
    Clin Transl Sci; 2023 Jun; 16(6):987-1001. PubMed ID: 36967488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transporter-mediated drug-drug interactions.
    Müller F; Fromm MF
    Pharmacogenomics; 2011 Jul; 12(7):1017-37. PubMed ID: 21787191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
    Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Amino Acid/Drug Transporters for Renal Transport of [
    Ono M; Baden A; Okudaira H; Kobayashi M; Kawai K; Oka S; Yoshimura H
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27754421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.